Results 21 to 30 of about 6,967,236 (252)

A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes

Technology in Cancer Research & Treatment, 2021
Triple-negative breast cancer is a heterogeneous disease with different molecular and histological subtypes. The Androgen receptor is expressed in a portion of triple-negative breast cancer cases and the activation of the androgen receptor pathway is ...
Taobo Hu, Guiyang Zhao, Yiqiang Liu, Mengping Long   +3 more
doaj   +1 more source

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines [PDF]

, 2011
Breakthrough Breast CancerBackground: Gonadotrophin releasing hormone (GnRH) analogs lower estrogen levels in pre-menopausal breast cancer patients. GnRH receptor (GnRH-R) activation also directly inhibits the growth of certain cells.
Sims Andrew H, Faratian Dana, Miller, Nicola, Sims, Andrew H., Morgan, Kevin, Miller Nicola, Millar, Robert P., Langdon, Simon P., Ilgin Cagnan, Sims, Andrew, Dana Faratian, Robert P Millar, Meyer, Colette, Simon P Langdon, Colette Meyer, Harrison David J, Cagnan, Ilgin, Nicola Miller, Morgan Kevin, Millar Robert P, David J Harrison, Faratian, Dana, Langdon Simon P, Kevin Morgan, Meyer Colette, Cagnan Ilgin, Andrew H Sims, Harrison, David J.   +27 more
core   +2 more sources

Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors

Frontiers in Oncology, 2023
Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2).
Ruoyan Qin, Jie Qian, Mengjun Shan, Guangxin Ruan, Xiaofeng Yang, Yanwen Wang, Lingshuang Liu   +6 more
doaj   +1 more source

A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway [PDF]

Einstein (São Paulo)
Introduction Triple-negative breast cancer is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This phenotype renders triple-negative
Isabele Pardo, Pedro Brecheret Fagundes, Rafael Santana de Oliveira, Paulo Vidal Campregher   +3 more
doaj   +1 more source

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review

Technology in Cancer Research & Treatment, 2023
Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and ...
Boya Lu MD, Elango Natarajan PhD, Hanumantha Rao Balaji Raghavendran PhD, Uma Devi Markandan PhD   +3 more
doaj   +1 more source

FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control

Frontiers in Oncology, 2019
Background: Triple negative breast cancers are aggressive, enriched with cancer stem cells, and lack effective targeted therapies with little side effects.Methods: We isolated cancer stem cells from two triple negative breast cancer cell lines via cell ...
Xiaofeng Dai, Shuo Zhang, Hongye Cheng, Dongyan Cai, Dongyan Cai, Xiao Chen, Zhaohui Huang, Zhaohui Huang   +7 more
doaj   +1 more source

Radiological diagnostics of triple negative breast cancer: a review

Acta Medica Lituanica, 2011
Background. Triple negative breast cancer has a poor prognosis. Therefore, it is vital to detect this subtype of breast cancer in its early stage. The imaging features of this clinically important subtype of breast cancer are not well known.
Sigutė STADALNYKAITĖ, Rūta BRIEDIENĖ
doaj   +1 more source

Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin

Breast Cancer: Basic and Clinical Research, 2009
In the current study, we sought to examine the effects of curcumin in a specific type of breast cancer called triple negative breast cancer. These cancers lack expression of the estrogen and progesterone receptors and do not over-express HER2.
Danica L. Rowe, Tuba Ozbay, Ruth M. O’Regan, Rita Nahta   +3 more
doaj   +2 more sources

Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device

Discover Oncology, 2023
Purpose Triple-negative breast cancer continues to be one of the leading causes of death in women, making up 7% of all cancer deaths. Tumor-treating electric fields are low-energy, low-frequency oscillating electric fields that induce an anti ...
Austin R. Smothers, Jason R. Henderson, John J. O’Connell, Jonathan M. Stenbeck, Delphine Dean, Tyler G. Harvey, Brian W. Booth   +6 more
doaj   +1 more source

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]

, 2012
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali, Smoth, Ke-Seay, Crown, John, Piccart-Gebhart, Martine, Buyse, Marc, Hainaut, Pierre, Azambuja, Evandro De, Falagan-Lotsch, Priscila, Quinaux, Emmanuel, Dolci, M Stella, Larsimont, Denis, Oakman, Catherine, Francis, Prudence A, Fernández-Cuesta, Lynnette, Dell'orto, Patrizia   +16 more
core   +2 more sources